FDA expands label for Teva's Azilect; Ackman says he 'followed the rules';

@FiercePharma: Top-read on FP this weekend: AbbVie readies production in anticipation of hep C treatment approval. Story | Follow @FiercePharma

@TracyStaton: Would you pay $84K for Sovaldi yourself if you had hep C? Check out this discussion FiercePharma's LinkedIn group: Conversation | Follow @TracyStaton

@EricPFierce: ICYMI Friday: The #FDA and #EMA see the world of inspections differently and Ranbaxy case shows that. Article | Follow @EricPFierce

@CarlyHFierce: Could automating production solve #India's #manufacturing problems? More | Follow @CarlyHFierce

@JustinHFierce: Because pigs, apparently, get all the action: $NVS out with fast-acting Florvio to combat swine respiratory disease. More | Follow @JustinHFierce

> The FDA has expanded the label for Teva's ($TEVA) Azilect for treatment across all stages of Parkinson's disease. Release

> Valeant's takeover partner ($VRX), Bill Ackman, says he followed the rules with his Allergan ($AGN) investment. Report

> The FDA has approved Valeant's Jublia for toenail fungus. Story

> The biggest spike in ADHD medication is among women between the ages of 19 and 34, a recent report says. More

> Inflammation may help explain the link between depression and diabetes. More

> Psoriasis negatively impacts the qualify of life of both patients and the people who live with them, a new study shows. Report

Medical Device News

@FierceMedDev: ICYMI Friday: Kleiner Perkins, TPG-backed heart transplant monitor company files for $50M IPO. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI Friday: Ethicist: Recycling medical equipment from the dead OK. Story | Follow @VarunSaxena2

@MichaelGFierce: Singapore team designs nanotechnology glaucoma treatment for sustained release. FierceDrugDelivery article | Follow @MichaelGFierce

@EmilyWFierce: New test that pinpoints multiple genes in a tumor could replace companion Dx as a tool for diagnosing. Reuters article | Follow @EmilyWFierce

> Devicemakers stash money abroad for tax purposes, possibly fueling deals overseas. Article

> Kamra gets FDA panel OK, but safety concerns nag. Story

> Dutch company develops 3-D printing process for lenses and glasses. More

> New MRI technique could speed up diagnosis for traumatic brain injury. Report

Biotech News

@FierceBiotech: ICYM @EricPFierce's #ASCO14 chat with @JonEPVantage, review the recap here. Chat | Follow @FierceBiotech

@JohnCFierce: $MRK's ability to charge into a triple-drug study and get it through the clinic will say a lot about the R&D culture under Perlmutter. | Follow @JohnCFierce

@DamianFierce: $MRK's $3.85B $IDIX deal is a roughly 340% premium on Friday's close. Release | Follow @DamianFierce

@EmilyMFierce: Antibiotic Resistance Revitalizes Century-Old Virus Therapy. More from Scientific American | Follow @EmilyMFierce

> Biogen Idec racks up another blockbuster FDA approval, this time for hemophilia. Article

> IPO-hopeful Kite Pharma inks an NIH licensing deal on hot TCR tech. Story

> Ackman says Allergan shareholders are on board for Valeant's $53B takeover. Report

> Merck scoops up troubled Idenix's hep C drugs in $3.85B buyout. News

CRO News

> CROs unite to kick-start a biotech's pipeline. Report

> Parexel eyes a $150M share buyback. Item

> Celerion moves into Singapore amid Asian expansion. Article

> InVentiv signs on to market 3-D printed drugs. Story

> Bristol-Myers deepens its ties to Biocon's CRO and Indian R&D. More

Biotech IT News

> FDA opens adverse-event data to app developers in first wave of openFDA. More

> EU ombudsman probes link between AbbVie case and trial transparency U-turn. Story

> Venter Institute wins $25M NIH grant to apply sequencing tech to infectious diseases. Report

> CamCog adds iPad trial tech for cognitive safety, abuse potential. Item

> Lilly, Novartis and Pfizer join with Broad Institute for bioinformatics challenge. Article

And Finally... Oral contraceptives may impact what traits women desire in an imaginary mate. More

Suggested Articles

It’s been a rocky road for BMS’ immuno-oncology duo in previously untreated lung cancer, but a new addition to the regimen might hold the ticket.

Novartis’ Zolgensma launch has been anything but boring: First a record price, then a data scandal and now a manufacturing-related delay in Europe.

As CEO Paul Hudson focuses Sanofi's R&D program on immuno-oncology and gene therapies, Sanofi is readying a vaccine plant to make viral vectors.